Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | YAP1 | P46937 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15075586 | 1.00 | ACACB (0.49) | ACACBUSP30BACE1P2RX7CYP3A4 | |
| SCHEMBL16214228 | 0.93 | ACACB (0.54) | ACACBUSP30BACE1P2RX7YAP1 | |
| SCHEMBL18459339 | 0.87 | YAP1 (0.48) | BACE1P2RX7CYP3A4TSHRYAP1 | |
| SCHEMBL18459337 | 0.87 | YAP1 (0.48) | BACE1P2RX7CYP3A4TSHRYAP1 | |
| SCHEMBL15083952 | 0.87 | CCR1 (0.48) | BACE1P2RX7CYP3A4TSHRSYK | |
| SCHEMBL16187531 | 0.85 | ACACB (0.54) | ACACBUSP30 | |
| SCHEMBL18176134 | 0.85 | ACACB (0.54) | ACACBUSP30 | |
| SCHEMBL15901017 | 0.83 | ACACB (0.59) | ACACBCYP3A4TSHR | |
| SCHEMBL15048018 | 0.82 | ACACB (0.63) | ACACB | |
| SCHEMBL15048067 | 0.82 | ACACB (0.63) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794586-B1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-04-20 | — | — | EP | disclosed |
| US-8530460-B2 | Azetidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20130158004-A1 | Azetidine Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158004-A1 | Azetidine Derivatives | GPR119, LIPE, LPL | ACACB 870/4885USP30 680/4885BACE1 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.